Skip to main content


Non-Small Cell Lung Cancer

Featured

Guideline Updates
The NCCN released an update to include cemiplimab-rwlc as a preferred, category 1, treatment option for PD-L1 expression-positive NSCLC ≥50%.
News
Study results show nivolumab monotherapy is effective for previously treated advanced NSCLC in real-world practice.
News
Higher out-of-pocket costs for TKIs are associated with decreased therapy adherence among patients with EGFR- and ALK-…
Quiz
True or False: Higher out-of-pocket costs for TKIs among patients with EGFR- and ALK-positive advanced NSCLC are…
News
Study findings show TKI therapy, immunotherapy, and chemotherapy are relatively small drivers of unplanned acute…
Back to Top